2022 World Conference on Lung Cancer (ePosters)-EP08.02-160. A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy

EP08.02-160. A Pooled Efficacy and Safety Analysis of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Immunotherapy

Back to course

Pdf Summary

A pooled analysis of two phase II trials was conducted to evaluate the effectiveness and safety of combining anlotinib with docetaxel in advanced non-small cell lung cancer (NSCLC) patients who had previously received immunotherapy. The analysis included 73 patients who had progressed after initial platinum-based chemotherapy. <br /><br />The study found that the combination of anlotinib plus docetaxel demonstrated significant efficacy and an acceptable safety profile in these patients. The median progression-free survival was 7.60 months in the combination group, compared to 2.50 months in the docetaxel-only group. Additionally, the overall response rate was higher in the combination group. <br /><br />The most common grade 3 treatment-related adverse events in the combination group included neutropenia, leukopenia, and oral mucositis, while leukopenia and pneumonia were more frequent in the docetaxel-only group. <br /><br />These findings suggest that the combination of anlotinib plus docetaxel could be a viable option for advanced NSCLC patients who have received immune checkpoint inhibitors. However, further research is needed to validate these results.

Asset Subtitle

Lin Wu

Meta Tag

Speaker Lin Wu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

pooled analysis

phase II trials

effectiveness

safety

anlotinib

docetaxel

advanced NSCLC

progression-free survival

adverse events

immune checkpoint inhibitors